+

CN109996872A - A kind of EGFR single domain antibody CART and its application for treating tumour - Google Patents

A kind of EGFR single domain antibody CART and its application for treating tumour Download PDF

Info

Publication number
CN109996872A
CN109996872A CN201780064335.1A CN201780064335A CN109996872A CN 109996872 A CN109996872 A CN 109996872A CN 201780064335 A CN201780064335 A CN 201780064335A CN 109996872 A CN109996872 A CN 109996872A
Authority
CN
China
Prior art keywords
domain antibody
egfr
cart
application
single domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780064335.1A
Other languages
Chinese (zh)
Inventor
张继帅
李胜华
栗红建
赵杨杨
余祥
郑孟韬
何昱
何鹏华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Pregene Biopharma Co ltd
Original Assignee
Shenzhen Pregene Biopharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Pregene Biopharma Co ltd filed Critical Shenzhen Pregene Biopharma Co ltd
Publication of CN109996872A publication Critical patent/CN109996872A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了一种EGFR单域抗体改造的CART细胞，所述CART细胞可用于治疗肿瘤。还提供了人源化的EGFR单域抗体基因及其编码的单域抗体，EGFR CAR基因及其编码的EGFR CAR嵌合抗原受体，以及含有EGFR CAR基因的慢病毒载体Pre‑Lenti‑EF1‑EGFR CAR。

Provided are EGFR single-domain antibody-modified CART cells, which can be used to treat tumors. Also provided are a humanized EGFR single-domain antibody gene and the single-domain antibody it encodes, an EGFR CAR gene and the EGFR CAR chimeric antigen receptor it encodes, and a lentiviral vector containing the EGFR CAR gene, Pre-Lenti-EF1-EGFR CAR.

Description

PCT国内申请，说明书已公开。PCT domestic application, the description has been published.

Claims (13)

PCT国内申请，权利要求书已公开。PCT domestic application, the claims have been published.
CN201780064335.1A 2017-07-20 2017-07-20 A kind of EGFR single domain antibody CART and its application for treating tumour Pending CN109996872A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/093652 WO2019014891A1 (en) 2017-07-20 2017-07-20 Egfr single-domain antibody cart for treating tumor and application thereof

Publications (1)

Publication Number Publication Date
CN109996872A true CN109996872A (en) 2019-07-09

Family

ID=65015418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780064335.1A Pending CN109996872A (en) 2017-07-20 2017-07-20 A kind of EGFR single domain antibody CART and its application for treating tumour

Country Status (2)

Country Link
CN (1) CN109996872A (en)
WO (1) WO2019014891A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022127871A1 (en) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384825A (en) * 2015-08-11 2016-03-09 南京传奇生物科技有限公司 Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof
CN106636003A (en) * 2017-01-24 2017-05-10 北京普瑞金科技有限公司 Completely humanized EGFRvIII chimeric antigen receptor T cell and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
US9447194B2 (en) * 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384825A (en) * 2015-08-11 2016-03-09 南京传奇生物科技有限公司 Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof
WO2017025038A1 (en) * 2015-08-11 2017-02-16 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
CN106636003A (en) * 2017-01-24 2017-05-10 北京普瑞金科技有限公司 Completely humanized EGFRvIII chimeric antigen receptor T cell and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREA BELL等: "Differential tumor-targeting abilities of three single-domain antibody formats", 《CANCER LETTERS》 *
IAN M. TOMLINSON等: "The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops", 《J. MOL. BIOL.》 *
张曼泽等: "嵌合抗原受体修饰的T细胞在实体肿瘤治疗中的研究进展", 《免疫学杂志》 *

Also Published As

Publication number Publication date
WO2019014891A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
JOP20200078A1 (en) Antibodies specific to cd47 and pd-l1
CN109790222A (en) Antibody against claudin 18A2 and its application
CN111601825A (en) Fully human anti-B cell maturation antigen (BCMA) single-chain antibody and its application
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
CN115715298A (en) BCMA and CD19 targeting chimeric antigen receptor CAR or CAR constructs and uses thereof
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2015112805A8 (en) Human antibodies to pd-l1
AU2018282094A1 (en) Antibodies that specifically bind PD-1 and methods of use
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
TN2017000173A1 (en) Antibody drug conjugates
MX2020004410A (en) Antibody compositions for tumor treatment.
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
CN110337449A (en) Anti- PD-L1 antibody and its application
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
WO2016160618A3 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
WO2018035084A8 (en) Monovalent asymmetric tandem fab bispecific antibodies
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
MX2021006389A (en) Cd3 antibody and pharmaceutical use thereof.
EP4538295A3 (en) Antigen binding molecules and methods of use thereof
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
PH12019500571A1 (en) Anti-pd-1 antibodies
MX2021003636A (en) CHIMERIC ANTIGEN RECEPTOR.
WO2017079479A8 (en) Neutralizing antibodies to hiv-1 gp41 and their use
CN114651013A (en) Binding molecules specific for CD39 and uses thereof
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190709

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载